Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-12

AUTHORS

Antoine Adenis, Christelle de la Fouchardiere, Bernard Paule, Pascal Burtin, David Tougeron, Jennifer Wallet, Louis-Marie Dourthe, Pierre-Luc Etienne, Laurent Mineur, Stéphanie Clisant, Jean-Marc Phelip, Andrew Kramar, Thierry Andre

ABSTRACT

BACKGROUND: Randomized trials have shown a survival benefit for regorafenib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard therapies. We evaluated survival and safety outcomes in patients treated with regorafenib in a real-life setting. METHODS: REBECCA is a cohort study nested within a compassionate use program designed to evaluate survival, safety, and potential prognostic factors for outcome associated with regorafenib in patients with mCRC refractory to standard therapies. Treatment effects according to various patient and tumour characteristics were evaluated using univariate and multivariate Cox proportional hazards regression models. RESULTS: Of 1178 patients in the compassionate use program, 654 were in the full analysis set. Median follow-up was 16.5 months. Median survival was 5.6 months. The 12-month survival rate was 22 %. Survival was independently and unfavourably affected by the following variables: poor performance status, short time from initial diagnosis of metastases to the start of regorafenib, low initial regorafenib dose, >3 metastatic sites, presence of liver metastases, and KRAS mutations. We identified prognostic groups of patients with low, intermediate, and high risk of death, with a median survival of 9.2, 5.2, and 2.5 months, respectively. Five-hundred-twenty-four patients (80 %) experienced at least one regorafenib-related adverse event, most commonly, fatigue, hand-foot skin reaction, diarrhea, anorexia, arterial hypertension, and mucositis. CONCLUSION: The safety and efficacy profile of regorafenib in REBECCA are similar to those in randomized trials. Our prognostic model identified subgroups of mCRC patients who derived a minimal and maximum benefit from regorafenib. TRIAL REGISTRATION: Clinicaltrials.gov NCT02310477 . More... »

PAGES

412

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-016-2440-9

DOI

http://dx.doi.org/10.1186/s12885-016-2440-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1044485147

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27389564


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Compassionate Use Trials", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins p21(ras)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Centre Oscar Lambret", 
          "id": "https://www.grid.ac/institutes/grid.452351.4", 
          "name": [
            "Medical Oncology, Centre Oscar Lambret and Catholic University, Lille, France", 
            "Department of Medical Oncology, Centre Oscar Lambret, 3, rue F Combemale, 59000, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adenis", 
        "givenName": "Antoine", 
        "id": "sg:person.01303404424.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303404424.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Medical Oncology, Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de la Fouchardiere", 
        "givenName": "Christelle", 
        "id": "sg:person.01304763136.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304763136.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology, Paul Brousse University Hospital, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paule", 
        "givenName": "Bernard", 
        "id": "sg:person.0652052661.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652052661.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Medical Oncology, Gustave Roussy, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burtin", 
        "givenName": "Pascal", 
        "id": "sg:person.01302137250.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302137250.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Poitiers", 
          "id": "https://www.grid.ac/institutes/grid.411162.1", 
          "name": [
            "Gastroenterology, University Hospital, Poitiers, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tougeron", 
        "givenName": "David", 
        "id": "sg:person.0635311430.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635311430.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Oscar Lambret", 
          "id": "https://www.grid.ac/institutes/grid.452351.4", 
          "name": [
            "Methodology and Biostatistics, Centre Oscar Lambret, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wallet", 
        "givenName": "Jennifer", 
        "id": "sg:person.013250661151.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013250661151.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology, Clinique Sainte Anne, Strasbourg, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dourthe", 
        "givenName": "Louis-Marie", 
        "id": "sg:person.0645237204.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645237204.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology, Hopital Priv\u00e9 des C\u00f4tes d\u2019Armor, Pl\u00e9rin, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Etienne", 
        "givenName": "Pierre-Luc", 
        "id": "sg:person.0712551042.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712551042.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Sainte Catherine", 
          "id": "https://www.grid.ac/institutes/grid.482015.a", 
          "name": [
            "Radiation and Medical Oncology, Institut Sainte-Catherine, Avignon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mineur", 
        "givenName": "Laurent", 
        "id": "sg:person.01167577531.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167577531.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Oscar Lambret", 
          "id": "https://www.grid.ac/institutes/grid.452351.4", 
          "name": [
            "Clinical Research Unit, Centre Oscar Lambret, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clisant", 
        "givenName": "St\u00e9phanie", 
        "id": "sg:person.0762650444.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762650444.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Gastroenterology, University Hospital, Saint Etienne, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Phelip", 
        "givenName": "Jean-Marc", 
        "id": "sg:person.0775434225.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775434225.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Oscar Lambret", 
          "id": "https://www.grid.ac/institutes/grid.452351.4", 
          "name": [
            "Methodology and Biostatistics, Centre Oscar Lambret, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kramar", 
        "givenName": "Andrew", 
        "id": "sg:person.0660025350.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660025350.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology, Saint Antoine Hospital, and University Pierre et Marie Curie (UMPC), Paris VI, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Andre", 
        "givenName": "Thierry", 
        "id": "sg:person.0724247022.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724247022.53"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-1900", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018407352"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)61900-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020430219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)70156-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025540135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00138-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049163362"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.33.3_suppl.678", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083955312"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-12", 
    "datePublishedReg": "2016-12-01", 
    "description": "BACKGROUND: Randomized trials have shown a survival benefit for regorafenib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard therapies. We evaluated survival and safety outcomes in patients treated with regorafenib in a real-life setting.\nMETHODS: REBECCA is a cohort study nested within a compassionate use program designed to evaluate survival, safety, and potential prognostic factors for outcome associated with regorafenib in patients with mCRC refractory to standard therapies. Treatment effects according to various patient and tumour characteristics were evaluated using univariate and multivariate Cox proportional hazards regression models.\nRESULTS: Of 1178 patients in the compassionate use program, 654 were in the full analysis set. Median follow-up was 16.5\u00a0months. Median survival was 5.6\u00a0months. The 12-month survival rate was 22\u00a0%. Survival was independently and unfavourably affected by the following variables: poor performance status, short time from initial diagnosis of metastases to the start of regorafenib, low initial regorafenib dose, >3 metastatic sites, presence of liver metastases, and KRAS mutations. We identified prognostic groups of patients with low, intermediate, and high risk of death, with a median survival of 9.2, 5.2, and 2.5\u00a0months, respectively. Five-hundred-twenty-four patients (80\u00a0%) experienced at least one regorafenib-related adverse event, most commonly, fatigue, hand-foot skin reaction, diarrhea, anorexia, arterial hypertension, and mucositis.\nCONCLUSION: The safety and efficacy profile of regorafenib in REBECCA are similar to those in randomized trials. Our prognostic model identified subgroups of mCRC patients who derived a minimal and maximum benefit from regorafenib.\nTRIAL REGISTRATION: Clinicaltrials.gov NCT02310477 .", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-016-2440-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "name": "Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program", 
    "pagination": "412", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d3e651b2795b8f42989d476eb5457239aa27778ac1f791fa042fcd2eda6d276c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27389564"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-016-2440-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1044485147"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-016-2440-9", 
      "https://app.dimensions.ai/details/publication/pub.1044485147"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:44", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70068_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-016-2440-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2440-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2440-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2440-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2440-9'


 

This table displays all metadata directly associated to this object as RDF triples.

272 TRIPLES      21 PREDICATES      54 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-016-2440-9 schema:about N0398b3431c334746a479e8d14e60598a
2 N0b5eaaf918bc410a9d7b8007d0781523
3 N42d8b22c947a44138262544c522d4aa8
4 N45dc21912e7a4083b952f2e3fe26186c
5 N5d4dc2167c354e9fb424a7db8c42d44c
6 N5ee83a6b8856435da68d23bb89bd94a1
7 N6775b9769b7b4e53aae881045d1f232d
8 N6f1aee78da9540eeab9c865363847697
9 N78700b4aa1604575bb5df11ba8cd7d49
10 N8f5d9d4404ce46d59286a9c873d714b1
11 N9d054b96292849128b4846b0e07b9a19
12 Na65d15ea394f43a9acb2c6b84143f869
13 Nc08cd17b6093466685bbbab775e64686
14 Nc9dc9641aebb4c3d83511b0396de4313
15 Ncf9ebfbd7e944ae08294ff8af064453e
16 Nd16595a2722a40f9a48fd6e025cfcfc9
17 Nd19cf7930883410b97a99841f20598bb
18 Nef9fab49bf914bfc88a50bd952924542
19 Nf354859bb0854f26bd77b96982a28fc1
20 Nf993a173e729438687126d8c0e1ab695
21 anzsrc-for:11
22 anzsrc-for:1112
23 schema:author Nef97fbe331774b618dcc3c3f0072d84a
24 schema:citation https://doi.org/10.1016/s0140-6736(12)61900-x
25 https://doi.org/10.1016/s1470-2045(15)00138-2
26 https://doi.org/10.1016/s1470-2045(15)70156-7
27 https://doi.org/10.1158/1078-0432.ccr-11-1900
28 https://doi.org/10.1200/jco.2015.33.3_suppl.678
29 schema:datePublished 2016-12
30 schema:datePublishedReg 2016-12-01
31 schema:description BACKGROUND: Randomized trials have shown a survival benefit for regorafenib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard therapies. We evaluated survival and safety outcomes in patients treated with regorafenib in a real-life setting. METHODS: REBECCA is a cohort study nested within a compassionate use program designed to evaluate survival, safety, and potential prognostic factors for outcome associated with regorafenib in patients with mCRC refractory to standard therapies. Treatment effects according to various patient and tumour characteristics were evaluated using univariate and multivariate Cox proportional hazards regression models. RESULTS: Of 1178 patients in the compassionate use program, 654 were in the full analysis set. Median follow-up was 16.5 months. Median survival was 5.6 months. The 12-month survival rate was 22 %. Survival was independently and unfavourably affected by the following variables: poor performance status, short time from initial diagnosis of metastases to the start of regorafenib, low initial regorafenib dose, >3 metastatic sites, presence of liver metastases, and KRAS mutations. We identified prognostic groups of patients with low, intermediate, and high risk of death, with a median survival of 9.2, 5.2, and 2.5 months, respectively. Five-hundred-twenty-four patients (80 %) experienced at least one regorafenib-related adverse event, most commonly, fatigue, hand-foot skin reaction, diarrhea, anorexia, arterial hypertension, and mucositis. CONCLUSION: The safety and efficacy profile of regorafenib in REBECCA are similar to those in randomized trials. Our prognostic model identified subgroups of mCRC patients who derived a minimal and maximum benefit from regorafenib. TRIAL REGISTRATION: Clinicaltrials.gov NCT02310477 .
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree true
35 schema:isPartOf N4d805c64f6484b15bfe3407e25b49105
36 N9940d7edfa1d41a8b41a5746c3e2ad70
37 sg:journal.1024632
38 schema:name Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program
39 schema:pagination 412
40 schema:productId Naa4e58463298443c9bc32c49b1796dc0
41 Nbd5c28d053f54b7589af70a198fbb016
42 Nbe0d0cbf8a92434b8a7c79932f458266
43 Nc204dc717ad8462fb8ce49f528fea86d
44 Ne72d56994ac345bc98a80a90e43b3848
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044485147
46 https://doi.org/10.1186/s12885-016-2440-9
47 schema:sdDatePublished 2019-04-11T12:44
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher Nd91bf7f7490649f08089b0db6e50027c
50 schema:url https://link.springer.com/10.1186%2Fs12885-016-2440-9
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N0398b3431c334746a479e8d14e60598a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
55 schema:name Neoplasm Metastasis
56 rdf:type schema:DefinedTerm
57 N04e6ab5d356b4124863171dbda0d89ad rdf:first sg:person.0712551042.45
58 rdf:rest Ne13a63b613664552afb432c541346ef9
59 N07efa5f2d666481081a6fac52e1dbf08 rdf:first sg:person.0762650444.97
60 rdf:rest N8cb399667225415581b70d4f36afc762
61 N0b5eaaf918bc410a9d7b8007d0781523 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Survival Analysis
63 rdf:type schema:DefinedTerm
64 N0d5d8fca371e4478bcb3f6314f74f0e1 schema:name Medical Oncology, Hopital Privé des Côtes d’Armor, Plérin, France
65 rdf:type schema:Organization
66 N26fe4f6d93a74d61a67f40aa3cb3bbd3 schema:name Medical Oncology, Saint Antoine Hospital, and University Pierre et Marie Curie (UMPC), Paris VI, Paris, France
67 rdf:type schema:Organization
68 N2ff22f90ae5e45b08ae97bc66568da17 rdf:first sg:person.0660025350.21
69 rdf:rest N98ec36d57dbd4652b2874c8b9ebfe4d6
70 N42d8b22c947a44138262544c522d4aa8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Male
72 rdf:type schema:DefinedTerm
73 N45dc21912e7a4083b952f2e3fe26186c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Middle Aged
75 rdf:type schema:DefinedTerm
76 N4d805c64f6484b15bfe3407e25b49105 schema:volumeNumber 16
77 rdf:type schema:PublicationVolume
78 N57ea2b3b1087465aaae968e9a3f14752 schema:name Medical Oncology, Paul Brousse University Hospital, Villejuif, France
79 rdf:type schema:Organization
80 N5d4dc2167c354e9fb424a7db8c42d44c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Kaplan-Meier Estimate
82 rdf:type schema:DefinedTerm
83 N5ee83a6b8856435da68d23bb89bd94a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Female
85 rdf:type schema:DefinedTerm
86 N6775b9769b7b4e53aae881045d1f232d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Humans
88 rdf:type schema:DefinedTerm
89 N6ce7ff07083e43fe8f743d0c8b93cdba rdf:first sg:person.0645237204.25
90 rdf:rest N04e6ab5d356b4124863171dbda0d89ad
91 N6f1aee78da9540eeab9c865363847697 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Antineoplastic Agents
93 rdf:type schema:DefinedTerm
94 N7822fb71338c46229c0ddf96d646876c schema:name Medical Oncology, Clinique Sainte Anne, Strasbourg, France
95 rdf:type schema:Organization
96 N78700b4aa1604575bb5df11ba8cd7d49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Colorectal Neoplasms
98 rdf:type schema:DefinedTerm
99 N7db96156e5bf4e75ade753d66927e1c5 rdf:first sg:person.0635311430.72
100 rdf:rest Nff9f6a6814cb4f5186104a9545a2f62e
101 N85348f2d2e4347d0bb08a2289c361864 schema:name Gastroenterology, University Hospital, Saint Etienne, France
102 rdf:type schema:Organization
103 N8548b11832e845a2acecbdfcd8ec4e95 rdf:first sg:person.0652052661.75
104 rdf:rest Nc8569a3c2f2a495eac407cbc62716518
105 N8cb399667225415581b70d4f36afc762 rdf:first sg:person.0775434225.92
106 rdf:rest N2ff22f90ae5e45b08ae97bc66568da17
107 N8f5d9d4404ce46d59286a9c873d714b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Pyridines
109 rdf:type schema:DefinedTerm
110 N98ec36d57dbd4652b2874c8b9ebfe4d6 rdf:first sg:person.0724247022.53
111 rdf:rest rdf:nil
112 N9940d7edfa1d41a8b41a5746c3e2ad70 schema:issueNumber 1
113 rdf:type schema:PublicationIssue
114 N9d054b96292849128b4846b0e07b9a19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Mutation
116 rdf:type schema:DefinedTerm
117 Na65d15ea394f43a9acb2c6b84143f869 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Aged, 80 and over
119 rdf:type schema:DefinedTerm
120 Naa4e58463298443c9bc32c49b1796dc0 schema:name nlm_unique_id
121 schema:value 100967800
122 rdf:type schema:PropertyValue
123 Nafcc71aaeb3a4d6cb637b5e555b09d48 rdf:first sg:person.01304763136.25
124 rdf:rest N8548b11832e845a2acecbdfcd8ec4e95
125 Nbd5c28d053f54b7589af70a198fbb016 schema:name doi
126 schema:value 10.1186/s12885-016-2440-9
127 rdf:type schema:PropertyValue
128 Nbe0d0cbf8a92434b8a7c79932f458266 schema:name pubmed_id
129 schema:value 27389564
130 rdf:type schema:PropertyValue
131 Nc08cd17b6093466685bbbab775e64686 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Adult
133 rdf:type schema:DefinedTerm
134 Nc204dc717ad8462fb8ce49f528fea86d schema:name readcube_id
135 schema:value d3e651b2795b8f42989d476eb5457239aa27778ac1f791fa042fcd2eda6d276c
136 rdf:type schema:PropertyValue
137 Nc8569a3c2f2a495eac407cbc62716518 rdf:first sg:person.01302137250.23
138 rdf:rest N7db96156e5bf4e75ade753d66927e1c5
139 Nc9dc9641aebb4c3d83511b0396de4313 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Prognosis
141 rdf:type schema:DefinedTerm
142 Ncf9ebfbd7e944ae08294ff8af064453e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Cohort Studies
144 rdf:type schema:DefinedTerm
145 Nd16595a2722a40f9a48fd6e025cfcfc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Aged
147 rdf:type schema:DefinedTerm
148 Nd19cf7930883410b97a99841f20598bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Compassionate Use Trials
150 rdf:type schema:DefinedTerm
151 Nd91bf7f7490649f08089b0db6e50027c schema:name Springer Nature - SN SciGraph project
152 rdf:type schema:Organization
153 Ne13a63b613664552afb432c541346ef9 rdf:first sg:person.01167577531.59
154 rdf:rest N07efa5f2d666481081a6fac52e1dbf08
155 Ne72d56994ac345bc98a80a90e43b3848 schema:name dimensions_id
156 schema:value pub.1044485147
157 rdf:type schema:PropertyValue
158 Nef97fbe331774b618dcc3c3f0072d84a rdf:first sg:person.01303404424.36
159 rdf:rest Nafcc71aaeb3a4d6cb637b5e555b09d48
160 Nef9fab49bf914bfc88a50bd952924542 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Treatment Outcome
162 rdf:type schema:DefinedTerm
163 Nf354859bb0854f26bd77b96982a28fc1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Phenylurea Compounds
165 rdf:type schema:DefinedTerm
166 Nf993a173e729438687126d8c0e1ab695 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Proto-Oncogene Proteins p21(ras)
168 rdf:type schema:DefinedTerm
169 Nff9f6a6814cb4f5186104a9545a2f62e rdf:first sg:person.013250661151.38
170 rdf:rest N6ce7ff07083e43fe8f743d0c8b93cdba
171 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
172 schema:name Medical and Health Sciences
173 rdf:type schema:DefinedTerm
174 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
175 schema:name Oncology and Carcinogenesis
176 rdf:type schema:DefinedTerm
177 sg:journal.1024632 schema:issn 1471-2407
178 schema:name BMC Cancer
179 rdf:type schema:Periodical
180 sg:person.01167577531.59 schema:affiliation https://www.grid.ac/institutes/grid.482015.a
181 schema:familyName Mineur
182 schema:givenName Laurent
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167577531.59
184 rdf:type schema:Person
185 sg:person.01302137250.23 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
186 schema:familyName Burtin
187 schema:givenName Pascal
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302137250.23
189 rdf:type schema:Person
190 sg:person.01303404424.36 schema:affiliation https://www.grid.ac/institutes/grid.452351.4
191 schema:familyName Adenis
192 schema:givenName Antoine
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303404424.36
194 rdf:type schema:Person
195 sg:person.01304763136.25 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
196 schema:familyName de la Fouchardiere
197 schema:givenName Christelle
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304763136.25
199 rdf:type schema:Person
200 sg:person.013250661151.38 schema:affiliation https://www.grid.ac/institutes/grid.452351.4
201 schema:familyName Wallet
202 schema:givenName Jennifer
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013250661151.38
204 rdf:type schema:Person
205 sg:person.0635311430.72 schema:affiliation https://www.grid.ac/institutes/grid.411162.1
206 schema:familyName Tougeron
207 schema:givenName David
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635311430.72
209 rdf:type schema:Person
210 sg:person.0645237204.25 schema:affiliation N7822fb71338c46229c0ddf96d646876c
211 schema:familyName Dourthe
212 schema:givenName Louis-Marie
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645237204.25
214 rdf:type schema:Person
215 sg:person.0652052661.75 schema:affiliation N57ea2b3b1087465aaae968e9a3f14752
216 schema:familyName Paule
217 schema:givenName Bernard
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652052661.75
219 rdf:type schema:Person
220 sg:person.0660025350.21 schema:affiliation https://www.grid.ac/institutes/grid.452351.4
221 schema:familyName Kramar
222 schema:givenName Andrew
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660025350.21
224 rdf:type schema:Person
225 sg:person.0712551042.45 schema:affiliation N0d5d8fca371e4478bcb3f6314f74f0e1
226 schema:familyName Etienne
227 schema:givenName Pierre-Luc
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712551042.45
229 rdf:type schema:Person
230 sg:person.0724247022.53 schema:affiliation N26fe4f6d93a74d61a67f40aa3cb3bbd3
231 schema:familyName Andre
232 schema:givenName Thierry
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724247022.53
234 rdf:type schema:Person
235 sg:person.0762650444.97 schema:affiliation https://www.grid.ac/institutes/grid.452351.4
236 schema:familyName Clisant
237 schema:givenName Stéphanie
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762650444.97
239 rdf:type schema:Person
240 sg:person.0775434225.92 schema:affiliation N85348f2d2e4347d0bb08a2289c361864
241 schema:familyName Phelip
242 schema:givenName Jean-Marc
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775434225.92
244 rdf:type schema:Person
245 https://doi.org/10.1016/s0140-6736(12)61900-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1020430219
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1016/s1470-2045(15)00138-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049163362
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1016/s1470-2045(15)70156-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025540135
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1158/1078-0432.ccr-11-1900 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018407352
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1200/jco.2015.33.3_suppl.678 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083955312
254 rdf:type schema:CreativeWork
255 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
256 schema:name Medical Oncology, Gustave Roussy, Villejuif, France
257 rdf:type schema:Organization
258 https://www.grid.ac/institutes/grid.411162.1 schema:alternateName Centre Hospitalier Universitaire de Poitiers
259 schema:name Gastroenterology, University Hospital, Poitiers, France
260 rdf:type schema:Organization
261 https://www.grid.ac/institutes/grid.418116.b schema:alternateName Centre Léon Bérard
262 schema:name Medical Oncology, Centre Léon Bérard, Lyon, France
263 rdf:type schema:Organization
264 https://www.grid.ac/institutes/grid.452351.4 schema:alternateName Centre Oscar Lambret
265 schema:name Clinical Research Unit, Centre Oscar Lambret, Lille, France
266 Department of Medical Oncology, Centre Oscar Lambret, 3, rue F Combemale, 59000, Lille, France
267 Medical Oncology, Centre Oscar Lambret and Catholic University, Lille, France
268 Methodology and Biostatistics, Centre Oscar Lambret, Lille, France
269 rdf:type schema:Organization
270 https://www.grid.ac/institutes/grid.482015.a schema:alternateName Institut Sainte Catherine
271 schema:name Radiation and Medical Oncology, Institut Sainte-Catherine, Avignon, France
272 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...